<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Cytotoxic T-lymphocyte associated protein 4</title><meta name="description" content="Cytotoxic T-lymphocyte associated protein 4 , (CTLA-4) also known as CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA-4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers.[5] It acts as an &quot;off&quot; switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. It is encoded by..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="CTLA-4, CD152, Cytotoxic T-lymphocyte antigen 4"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Cytotoxic_T-lymphocyte_associated_protein_4"/><meta property="og:title" content="Cytotoxic T-lymphocyte associated protein 4"/><meta property="og:description" content="Cytotoxic T-lymphocyte associated protein 4 , (CTLA-4) also known as CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA-4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers.[5] It acts as an &quot;off&quot; switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. It is encoded by..."/><meta property="og:url" content="https://grokipedia.com/page/Cytotoxic_T-lymphocyte_associated_protein_4"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Cytotoxic T-lymphocyte associated protein 4"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:13.076Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Cytotoxic T-lymphocyte associated protein 4"/><meta name="twitter:description" content="Cytotoxic T-lymphocyte associated protein 4 , (CTLA-4) also known as CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA-4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers.[5] It acts as an &quot;off&quot; switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. It is encoded by..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="7b5c7c56bc0a705ea076dece8e023324-1300ebabc6a1a53f-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=7b5c7c56bc0a705ea076dece8e023324,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.49143807018498586,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>⌘</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>⌘</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cytotoxic-t-lymphocyte-associated-protein-4" class="transition-opacity hover:opacity-100 opacity-50">Cytotoxic T-lymphocyte associated protein 4</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history" class="transition-opacity hover:opacity-100 opacity-50">History</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#structure" class="transition-opacity hover:opacity-100 opacity-50">Structure</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-significance" class="transition-opacity hover:opacity-100 opacity-50">Clinical significance</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#germline-haploinsufficiency" class="transition-opacity hover:opacity-100 opacity-50">Germline haploinsufficiency</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-and-laboratory-manifestations" class="transition-opacity hover:opacity-100 opacity-50">Clinical and laboratory manifestations</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#treatment" class="transition-opacity hover:opacity-100 opacity-50">Treatment</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#agonists-to-reduce-immune-activity" class="transition-opacity hover:opacity-100 opacity-50">Agonists to reduce immune activity</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#antagonists-to-increase-immune-activity" class="transition-opacity hover:opacity-100 opacity-50">Antagonists to increase immune activity</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#interactions" class="transition-opacity hover:opacity-100 opacity-50">Interactions</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="cytotoxic-t-lymphocyte-associated-protein-4" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Cytotoxic T-lymphocyte associated protein 4<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>

















<!-- -->

















<!-- -->

























<!-- -->

























<!-- -->













































































































































































<!-- -->

























<!-- -->























































<!-- -->
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Cytotoxic T-lymphocyte associated protein 4</strong> , <strong>(CTLA-4)</strong> also known as <strong>CD152</strong> (<span class="inline text-[1em] leading-7">cluster of differentiation</span> 152), is a <span class="inline text-[1em] leading-7">protein receptor</span> that functions as an <span class="inline text-[1em] leading-7">immune checkpoint</span> and downregulates <span class="inline text-[1em] leading-7">immune responses</span>. CTLA-4 is constitutively expressed in <span class="inline text-[1em] leading-7">regulatory T cells</span> but only upregulated in conventional <span class="inline text-[1em] leading-7">T cells</span> after activation – a phenomenon which is particularly notable in cancers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> It acts as an &quot;off&quot; switch when bound to <span class="inline text-[1em] leading-7">CD80</span> or <span class="inline text-[1em] leading-7">CD86</span> on the surface of <span class="inline text-[1em] leading-7">antigen-presenting cells</span>. It is encoded by the <span class="inline text-[1em] leading-7">gene</span> <em>CTLA4</em> in humans.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The CTLA-4 protein is encoded by the <em>Ctla-4</em> gene in mice.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<h2 id="history" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The CTLA-4 gene was first cloned in 1987 from a cytotoxic T lymphocyte cDNA library, identifying it as a new member of the immunoglobulin superfamily.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_25qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> CTLA-4 was first identified in 1991 as a second receptor for the T cell costimulation ligand B7.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> In November 1995, the labs of Tak Wah Mak and Arlene Sharpe independently published their findings on the discovery of the function of CTLA-4 as a negative regulator of T-cell activation, by knocking out the gene in mice.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_65qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_75qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> Previous studies from several labs had used methods which could not definitively define the function of CTLA-4, and were contradictory.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">CTLA-4 is a member of the immunoglobulin superfamily that is expressed by activated T cells and transmits an inhibitory signal to T cells. CTLA-4 is homologous to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA-4 binds CD80 and CD86 with greater affinity and avidity than CD28 thus enabling it to outcompete CD28 for its ligands. CTLA-4 transmits an inhibitory signal to T cells,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_26abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_36abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> whereas CD28 transmits a stimulatory signal.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_76abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> CTLA-4 is also found in regulatory T cells (Tregs) and contributes to their inhibitory function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The mechanism by which CTLA-4 acts in T cells involves both cell-intrinsic and cell-extrinsic pathways. CTLA-4 recruits phosphatases such as SHP-2 to the T cell receptor (TCR), attenuating the signal by dephosphorylating key molecules like p52 SHC.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_26qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_36qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> More recent work has shown that CTLA-4 functions in vivo by capturing and removing CD80 and CD86 from the membranes of antigen-presenting cells via trans-endocytosis, thus making these unavailable for triggering of CD28.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In addition to that, it has been found that dendritic cell (DC) - Treg interaction causes sequestration of Fascin-1, an actin-bundling protein essential for immunological synapse formation and skews Fascin-1–dependent actin polarization in antigen presenting DCs toward the Treg cell adhesion zone. Although it is reversible upon T regulatory cell disengagement, this sequestration of essential cytoskeletal components causes a lethargic state of DCs, leading to reduced T cell priming. This suggests Treg-mediated immune suppression is a multi-step process. In addition to CTLA-4 CD80/CD86 interaction, fascin-dependent polarization of the cytoskeleton towards DC-Treg immune synapse may play a pivotal role.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">CTLA-4 may also function via modulation of cell motility and/or signaling through PI3 kinase.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> Early multiphoton microscopy studies observing T-cell motility in intact lymph nodes appeared to give evidence for the so-called ‘reverse-stop signaling model’.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> In this model CTLA-4 reverses the TCR-induced ‘stop signal’ needed for firm contact between T cells and antigen-presenting cells (APCs).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_67qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> However, those studies compared CTLA-4 positive cells, which are predominantly regulatory cells and are at least partially activated, with CTLA-4 negative naive T cells. The disparity of these cells in multiple regards may explain some of these results. Other groups who have analyzed the effect of antibodies to CTLA-4 in vivo have concluded little or no effect upon motility in the context of anergic T-cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Antibodies to CTLA-4 may exert additional effects when used in vivo, by binding and thereby depleting regulatory T cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<h2 id="structure" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Structure<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. The intracellular domain is similar to that of CD28, in that it has no intrinsic catalytic activity and contains one YVKM motif able to bind PI3K, PP2A and SHP-2 and one proline-rich motif able to bind SH3 containing proteins.</span>
<h2 id="clinical-significance" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Clinical significance<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Variants in this gene have been associated with <span class="inline text-[1em] leading-7">Type 1 diabetes</span>, <span class="inline text-[1em] leading-7">Graves&#x27; disease</span>, <span class="inline text-[1em] leading-7">Hashimoto&#x27;s thyroiditis</span>, <span class="inline text-[1em] leading-7">celiac disease</span>, <span class="inline text-[1em] leading-7">systemic lupus erythematosus</span>, thyroid-associated orbitopathy, <span class="inline text-[1em] leading-7">primary biliary cirrhosis</span> and other <span class="inline text-[1em] leading-7">autoimmune diseases</span>.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Polymorphisms of the CTLA-4 gene are associated with autoimmune diseases such as <span class="inline text-[1em] leading-7">rheumatoid arthritis</span>, <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> autoimmune thyroid disease and multiple sclerosis, though this association is often weak. In systemic lupus erythematosus (SLE), the splice variant sCTLA-4 is found to be aberrantly produced and found in the serum of patients with active SLE.</span>
<h3 id="germline-haploinsufficiency" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Germline haploinsufficiency<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Germline</span> <span class="inline text-[1em] leading-7">haploinsufficiency</span> of CTLA-4 leads to CTLA-4 deficiency or <span class="inline text-[1em] leading-7">CHAI disease</span> (CTLA4 haploinsufficiency with <span class="inline text-[1em] leading-7">autoimmune</span> infiltration), a rare genetic disorder of the immune system. This may cause a dysregulation of the immune system and may result in lymphoproliferation, autoimmunity, <span class="inline text-[1em] leading-7">hypogammaglobulinemia</span>, recurrent infections, and may slightly increase one’s risk of <span class="inline text-[1em] leading-7">lymphoma</span>. CTLA-4 mutations have first been described by a collaboration between the groups of Dr. Gulbu Uzel, Dr. Steven Holland, and Dr. Michael Lenardo from the <span class="inline text-[1em] leading-7">National Institute of Allergy and Infectious Disease</span>, Dr. Thomas Fleisher from the <span class="inline text-[1em] leading-7">NIH Clinical Center</span> at the <span class="inline text-[1em] leading-7">National Institutes of Health</span>, and their collaborators in 2014.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_jbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> In the same year a collaboration between the groups of Dr. Bodo Grimbacher, Dr. Shimon Sakaguchi, Dr. Lucy Walker and Dr. David Sansom and their collaborators described a similar phenotype.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">CTLA-4 mutations are inherited in an <span class="inline text-[1em] leading-7">autosomal dominant</span> manner. This means a person only needs one abnormal gene from one parent. The one normal copy is not enough to compensate for the one abnormal copy. Dominant inheritance means most families with CTLA-4 mutations have affected relatives in each <span class="inline text-[1em] leading-7">generation</span> on the side of the family with the <span class="inline text-[1em] leading-7">mutation</span>.</span>
<h4 id="clinical-and-laboratory-manifestations" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Clinical and laboratory manifestations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">Symptomatic patients with CTLA-4 mutations are characterized by an immune dysregulation syndrome including extensive <span class="inline text-[1em] leading-7">T cell</span> infiltration in a number of organs, including the gut, lungs, bone marrow, central nervous system <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> and kidneys. Most patients have diarrhea or <span class="inline text-[1em] leading-7">enteropathy</span>. <span class="inline text-[1em] leading-7">Lymphadenopathy</span> and <span class="inline text-[1em] leading-7">hepatosplenomegaly</span> are also common, as is autoimmunity. The organs affected by autoimmunity vary but include <span class="inline text-[1em] leading-7">thrombocytopenia</span>, <span class="inline text-[1em] leading-7">hemolytic anemia</span>, <span class="inline text-[1em] leading-7">thyroiditis</span>, type I diabetes, <span class="inline text-[1em] leading-7">psoriasis</span>, and <span class="inline text-[1em] leading-7">arthritis</span>. Respiratory infections are also common. Importantly, the clinical presentations and disease courses are variable with some individuals severely affected, whereas others show little manifestation of disease. This “<span class="inline text-[1em] leading-7">variable expressivity</span>,” even within the same family, can be striking and may be explained by differences in lifestyle, exposure to pathogens, treatment efficacy, or other genetic modifiers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_rcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_scqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> This condition is described to have incomplete penetrance of disease. <span class="inline text-[1em] leading-7">Penetrance</span> is said to be incomplete when some individuals fail to express the trait and seem completely asymptomatic, even though they carry the allele. The penetrance is estimated to be about 60%.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The clinical symptoms are caused by abnormalities of the immune system. Most patients develop reduced levels of at least one <span class="inline text-[1em] leading-7">immunoglobulin</span> isotype, and have low CTLA-4 protein expression in T regulatory cells, hyperactivation of effector T cells, low switched <span class="inline text-[1em] leading-7">memory B cells</span>, and progressive loss of circulating B cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup></span>
<h4 id="treatment" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Treatment<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">Once a diagnosis is made, the treatment is based on an individual’s clinical condition and may include standard management for autoimmunity and immunoglobulin deficiencies, such as immunosuppressive therapies and immunoglobulin replacement. Abatacept, a fusion protein of CTLA-4 and an antibody portion of IgG1, has been used for symptomatic control. A 2016 study reported treatment of a Korean CHAI disease patient with abatacept, which controlled immune activity, improved severe anemia and diarrhea (3 L/day), and ended a 3-year hospitalization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> For severe cases, hematopoietic stem cell transplantation (HSCT) is a potentially curative option, with a 2024 European study reporting 76.7% 3-year overall survival and remission in most surviving patients. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> Emerging approaches include autologous gene therapy to restore CTLA-4 expression, which is in early development as of 2024. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<h3 id="agonists-to-reduce-immune-activity" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Agonists to reduce immune activity<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The comparatively higher binding affinity of CTLA-4 than that of CD28 has made CTLA-4 a potential therapy for <span class="inline text-[1em] leading-7">autoimmune diseases</span>. Fusion proteins of CTLA-4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup> The fusion protein CTLA4-Ig is commercially available as Orencia (<span class="inline text-[1em] leading-7">abatacept</span>). A second generation form of CTLA4-Ig known as <span class="inline text-[1em] leading-7">belatacept</span> was approved by the FDA in 2011 based on favorable results from the randomized Phase III BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First Line Immunosuppression Trial) study. It was approved for renal transplantation in Epstein-Barr virus (EBV) seropositive patients.</span>
<h3 id="antagonists-to-increase-immune-activity" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Antagonists to increase immune activity<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Conversely, there is increasing interest in the possible therapeutic benefits of blocking CTLA-4 (using antagonistic antibodies against CTLA such as <span class="inline text-[1em] leading-7">ipilimumab</span>—FDA approved for melanoma in 2011—as a means of inhibiting immune system tolerance to tumours and thereby providing a potentially useful immunotherapy strategy for patients with cancer).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> This therapy was the first approved <span class="inline text-[1em] leading-7">immune checkpoint blockade</span> therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> Another is <span class="inline text-[1em] leading-7">tremelimumab</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The 2018 <span class="inline text-[1em] leading-7">Nobel Prize in Physiology or Medicine</span> was awarded to <span class="inline text-[1em] leading-7">James P. Allison</span> and <span class="inline text-[1em] leading-7">Tasuku Honjo</span> &quot;for their discovery of cancer therapy by inhibition of negative immune regulation&quot;.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup></span>
<h2 id="interactions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Interactions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">CTLA-4 has been shown to interact with:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">AP2M1,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1iiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></li>
<li class="text-[1em]">CD80,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_14iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1kiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup></li>
<li class="text-[1em]">CD86,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_16iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></li>
<li class="text-[1em]">PPP2R5A.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup>.</li>
</ul></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://May2017.archive.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000163599" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">GRCh38: Ensembl release 89: ENSG00000163599</a> – <span class="inline text-[1em] leading-7">Ensembl</span>, May 2017</span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://May2017.archive.ensembl.org/Mus_musculus/Gene/Summary?db=core;g=ENSMUSG00000026011" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">GRCm38: Ensembl release 89: ENSMUSG00000026011</a> – <span class="inline text-[1em] leading-7">Ensembl</span>, May 2017</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&amp;cmd=Link&amp;LinkName=gene_pubmed&amp;from_uid=1493" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Human PubMed Reference:&quot;</a>. <em>National Center for Biotechnology Information, U.S. National Library of Medicine</em>.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&amp;cmd=Link&amp;LinkName=gene_pubmed&amp;from_uid=12477" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Mouse PubMed Reference:&quot;</a>. <em>National Center for Biotechnology Information, U.S. National Library of Medicine</em>.</span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Syn NL, Teng MW, Mok TS, Soo RA (December 2017). &quot;De-novo and acquired resistance to immune checkpoint targeting&quot;. <em>The Lancet. Oncology</em>. <strong>18</strong> (12): e731 – e741. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fs1470-2045%2817%2930607-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/s1470-2045(17)30607-1</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29208439" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29208439</a>.</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P (1987). &quot;A new member of the immunoglobulin superfamily--CTLA-4&quot;. <em>Nature</em>. <strong>328</strong> (6127): 267–70. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/1987Natur.328..267B" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1987Natur.328..267B</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2F328267a0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/328267a0</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/3496540" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3496540</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:4316396" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4316396</a>.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Dariavach P, Mattéi MG, Golstein P, Lefranc MP (December 1988). &quot;Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains&quot;. <em>European Journal of Immunology</em>. <strong>18</strong> (12): 1901–5. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Feji.1830181206" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/eji.1830181206</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/3220103" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3220103</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:34071559" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">34071559</a>.</span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bashyam, Hema (June 2007). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118622" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;CTLA-4: From conflict to clinic&quot;</a>. <em>J Exp Med</em>. <strong>204</strong> (6): 1243. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1084%2Fjem.2046fta" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1084/jem.2046fta</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118622" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2118622</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/17632849" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">17632849</a>.</span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. (November 1995). &quot;Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4&quot;. <em>Science</em>. <strong>270</strong> (5238): 985–8. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/1995Sci...270..985W" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1995Sci...270..985W</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1126%2Fscience.270.5238.985" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1126/science.270.5238.985</a>. <span class="inline text-[1em] leading-7">JSTOR</span> <a href="https://www.jstor.org/stable/2888113" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2888113</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/7481803" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7481803</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:45993765" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">45993765</a>.</span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (November 1995). <a href="http://www.cell.com/immunity/pdf/1074-7613(95)90125-6.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4&quot;</a> (PDF). <em>Immunity</em>. <strong>3</strong> (5): 541–7. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2F1074-7613%2895%2990125-6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/1074-7613(95)90125-6</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/7584144" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7584144</a>.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pardoll DM (December 2012). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659410" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Immunology beats cancer: a blueprint for successful translation&quot;</a>. <em>Nature Immunology</em>. <strong>13</strong> (12): 1129–32. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fni.2392" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/ni.2392</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659410" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4659410</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23160205" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23160205</a>.</span></div></li><li id="https://doi.org/10.1084/jem.182.2.459" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1084/jem.182.2.459" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1084/jem.182.2.459</a></span></div></li><li id="https://doi.org/10.1084/jem.183.6.2541" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1084/jem.183.6.2541" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1084/jem.183.6.2541</a></span></div></li><li id="https://doi.org/10.1016/1074-7613(94)90071-x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1016/1074-7613(94)90071-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1016/1074-7613(94)90071-x</a></span></div></li><li id="https://doi.org/10.1126/science.270.5238.985" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1126/science.270.5238.985" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1126/science.270.5238.985</a></span></div></li><li id="https://doi.org/10.1038/356607a0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1038/356607a0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1038/356607a0</a></span></div></li><li id="https://doi.org/10.1002/(SICI)1521-4141(199911)29:11&lt;3596::AID-IMMU3596&gt;3.0.CO;2-Y" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1002/(SICI)1521-4141(199911)29:11" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1002/(SICI)1521-4141(199911)29:11</a>&lt;3596::AID-IMMU3596&gt;3.0.CO;2-Y</span></div></li><li id="https://doi.org/10.1126/science.282.5397.2263" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1126/science.282.5397.2263" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1126/science.282.5397.2263</a></span></div></li><li id="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.608024/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.608024/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.608024/full</a></span></div></li><li id="https://doi.org/10.1126/science.1202947" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1126/science.1202947" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1126/science.1202947</a></span></div></li><li id="https://doi.org/10.1084/jem.20160620" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1084/jem.20160620" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1084/jem.20160620</a></span></div></li><li id="https://doi.org/10.1371/journal.pone.0031391" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1371/journal.pone.0031391" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1371/journal.pone.0031391</a></span></div></li><li id="https://doi.org/10.1126/science.1131078" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1126/science.1131078" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1126/science.1131078</a></span></div></li><li id="https://doi.org/10.1111/j.1600-065X.2009.00770.x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1111/j.1600-065X.2009.00770.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1111/j.1600-065X.2009.00770.x</a></span></div></li><li id="https://doi.org/10.1038/ni.1790" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1038/ni.1790" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1038/ni.1790</a></span></div></li><li id="https://doi.org/10.1084/jem.20130579" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1084/jem.20130579" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1084/jem.20130579</a></span></div></li><li id="25" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Westra HJ, Martínez-Bonet M, Onengut-Gumuscu S, Lee A, Luo Y, Teslovich N, et al. (October 2018). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364548" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes&quot;</a>. <em>Nature Genetics</em>. <strong>50</strong> (10): 1366–1374. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fs41588-018-0216-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/s41588-018-0216-7</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364548" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6364548</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/30224649" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">30224649</a>.</span></div></li><li id="26" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. (September 2014). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371526" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4&quot;</a>. <em>Science</em>. <strong>345</strong> (6204): 1623–1627. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2014Sci...345.1623K" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2014Sci...345.1623K</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1126%2Fscience.1255904" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1126/science.1255904</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371526" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4371526</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25213377" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25213377</a>.</span></div></li><li id="27" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. (December 2014). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668597" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations&quot;</a>. <em>Nature Medicine</em>. <strong>20</strong> (12): 1410–1416. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fnm.3746" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/nm.3746</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668597" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4668597</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25329329" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25329329</a>.</span></div></li><li id="28" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kaninia S, Grammatikos A, Urankar K, Renowden SA, Patel NK, Gompels MM, Rice CM (August 2021). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358566" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;CNS demyelination associated with immune dysregulation and a novel <em>CTLA-4</em> variant&quot;</a>. <em>Multiple Sclerosis</em>. <strong>27</strong> (9): 1464–1467. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1177%2F1352458520963896" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1177/1352458520963896</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358566" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8358566</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/34097529" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">34097529</a>.</span></div></li><li id="29" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Grammatikos A, Johnston S, Rice CM, Gompels M (August 2021). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310858" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;A Family with a Novel CTLA4 Haploinsufficiency Mutation and Neurological Symptoms&quot;</a>. <em>Journal of Clinical Immunology</em>. <strong>41</strong> (6): 1411–1416. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2Fs10875-021-01027-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/s10875-021-01027-1</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310858" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8310858</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/33956248" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">33956248</a>.</span></div></li><li id="30" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Zeissig S, Petersen BS, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, et al. (December 2015). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512923" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Early-onset Crohn&#x27;s disease and autoimmunity associated with a variant in CTLA-4&quot;</a>. <em>Gut</em>. <strong>64</strong> (12): 1889–97. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1136%2Fgutjnl-2014-308541" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1136/gutjnl-2014-308541</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512923" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4512923</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25367873" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25367873</a>.</span></div></li><li id="31" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Lee S, Moon JS, Lee CR, Kim HE, Baek SM, Hwang S, et al. (January 2016). <a href="https://doi.org/10.1016%2Fj.jaci.2015.08.036" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4&quot;</a>. <em>The Journal of Allergy and Clinical Immunology</em>. <strong>137</strong> (1): 327–330. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.jaci.2015.08.036" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.jaci.2015.08.036</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26478010" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26478010</a>.</span></div></li><li id="https://doi.org/10.1016/j.jaci.2024.08.020" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1016/j.jaci.2024.08.020" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1016/j.jaci.2024.08.020</a></span></div></li><li id="https://sabaiglobal.com/gene-therapy-in-action-ctla4-haploinsufficiency/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://sabaiglobal.com/gene-therapy-in-action-ctla4-haploinsufficiency/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://sabaiglobal.com/gene-therapy-in-action-ctla4-haploinsufficiency/</a></span></div></li><li id="32" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Westhovens R, et al. (2004). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833769" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment&quot;</a>. <em><span class="inline text-[1em] leading-7">Arthritis Research&amp; Therapy</span></em>. <strong>6</strong> (Suppl 1): 86. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1186%2Far1128" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1186/ar1128</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833769" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2833769</a>.</span></div></li><li id="33" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pardoll DM (March 2012). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The blockade of immune checkpoints in cancer immunotherapy&quot;</a>. <em>Nature Reviews. Cancer</em>. <strong>12</strong> (4): 252–64. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fnrc3239" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/nrc3239</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4856023</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22437870" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22437870</a>.</span></div></li><li id="34" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nobelprize.org/prizes/medicine/2018/summary/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The Nobel Prize in Physiology or Medicine 2018&quot;</a>. <em>NobelPrize.org</em>. Retrieved 3 July 2023.</span></div></li><li id="35" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Follows ER, McPheat JC, Minshull C, Moore NC, Pauptit RA, Rowsell S, et al. (October 2001). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222163" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Study of the interaction of the medium chain mu 2 subunit of the clathrin-associated adapter protein complex 2 with cytotoxic T-lymphocyte antigen 4 and CD28&quot;</a>. <em>The Biochemical Journal</em>. <strong>359</strong> (Pt 2): 427–34. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1042%2F0264-6021%3A3590427" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1042/0264-6021:3590427</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222163" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1222163</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11583591" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11583591</a>.</span></div></li><li id="36" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Chuang E, Alegre ML, Duckett CS, Noel PJ, Vander Heiden MG, Thompson CB (July 1997). <a href="https://doi.org/10.4049%2Fjimmunol.159.1.144" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression&quot;</a>. <em>Journal of Immunology</em>. <strong>159</strong> (1): 144–51. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4049%2Fjimmunol.159.1.144" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4049/jimmunol.159.1.144</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/9200449" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">9200449</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:25449038" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25449038</a>.</span></div></li><li id="37" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Peach RJ, Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A, Linsley PS (September 1995). <a href="https://doi.org/10.1074%2Fjbc.270.36.21181" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28&quot;</a>. <em>The Journal of Biological Chemistry</em>. <strong>270</strong> (36): 21181–7. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1074%2Fjbc.270.36.21181" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1074/jbc.270.36.21181</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/7545666" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7545666</a>.</span></div></li><li id="38" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, et al. (March 2001). &quot;Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses&quot;. <em>Nature</em>. <strong>410</strong> (6828): 608–11. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2001Natur.410..608S" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2001Natur.410..608S</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2F35069118" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/35069118</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11279502" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11279502</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:4329622" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4329622</a>.</span></div></li><li id="https://www.uniprot.org/uniprotkb/P16410/entry" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uniprot.org/uniprotkb/P16410/entry" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uniprot.org/uniprotkb/P16410/entry</a></span></div></li><li id="39" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Baroja ML, Vijayakrishnan L, Bettelli E, Darlington PJ, Chau TA, Ling V, et al. (May 2002). <a href="https://doi.org/10.4049%2Fjimmunol.168.10.5070" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A&quot;</a>. <em>Journal of Immunology</em>. <strong>168</strong> (10): 5070–8. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4049%2Fjimmunol.168.10.5070" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4049/jimmunol.168.10.5070</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11994459" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11994459</a>.</span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Cytotoxic_T-lymphocyte_associated_protein_4" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw" id="_R_" async=""></script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\"}]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Cytotoxic_T-lymphocyte_associated_protein_4\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Cytotoxic_T-lymphocyte_associated_protein_4\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Cytotoxic_T-lymphocyte_associated_protein_4\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T5106,"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"# Cytotoxic T-lymphocyte associated protein 4\n\n| Available structures | |\n|----------------------|-|\n| PDB | Ortholog search: [PDBe](https://www.ebi.ac.uk/pdbe/searchResults.html?display=both\u0026term=P09793%20or%20P16410) [RCSB](https://www.rcsb.org/search?q=rcsb_polymer_entity_container_identifiers.reference_sequence_identifiers.database_name:UniProt%20AND%20rcsb_polymer_entity_container_identifiers.reference_sequence_identifiers.database_accession:P09793,P16410) |\n| List of PDB id codes | [3OSK](https://www.rcsb.org/structure/3OSK), [1AH1](https://www.rcsb.org/structure/1AH1), [1H6E](https://www.rcsb.org/structure/1H6E), [1I85](https://www.rcsb.org/structure/1I85), [1I8L](https://www.rcsb.org/structure/1I8L), [2X44](https://www.rcsb.org/structure/2X44), [3BX7](https://www.rcsb.org/structure/3BX7) |\n\n| Identifiers | |\n|-------------|-|\n| Aliases | [CTLA4](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/2505), ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12, cytotoxic T-lymphocyte associated protein 4 |\n| External IDs | [OMIM](Mendelian_Inheritance_in_Man \"Mendelian Inheritance in Man\"): [123890](https://omim.org/entry/123890); [MGI](Mouse_Genome_Informatics \"Mouse Genome Informatics\"): [88556](http://www.informatics.jax.org/marker/MGI:88556); [HomoloGene](HomoloGene \"HomoloGene\"): [3820](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026db=homologene\u0026dopt=HomoloGene\u0026list_uids=3820); [GeneCards](GeneCards \"GeneCards\"): [CTLA4](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CTLA4); [OMA](Orthologous_MAtrix \"Orthologous MAtrix\"):[CTLA4 - orthologs](https://omabrowser.org/oma/vps/ENSG00000163599) |\n\n| Gene location (Human) | |\n|-----------------------|-|\n| Chr. | [Chromosome 2 (human)](Chromosome_2_\\(human\\) \"Chromosome 2 \\(human\\)\")[1] |\n| Band | 2q33.2 |\n| Start | 203,853,888 [bp](Base_pair \"Base pair\")[1] |\n| End | 203,873,965 [bp](Base_pair \"Base pair\")[1] |\n\n| Gene location (Mouse) | |\n|-----------------------|-|\n| Chr. | Chromosome 1 (mouse)[2] |\n| Band | 1 C2|1 30.58 cM |\n| Start | 60,926,159 [bp](Base_pair \"Base pair\")[2] |\n| End | 60,954,991 [bp](Base_pair \"Base pair\")[2] |\n\n| RNA expression pattern | | | |\n|-----------------------|-|-|-|\n| Bgee | | | |\n| | Human | Mouse (ortholog) | |\n| Top expressed in | | | |\n| - lymph node | | | |\n| - appendix | | | |\n| - buccal mucosa cell | | | |\n| - gonad | | | |\n| - pancreatic epithelial cell | | | |\n| - testicle | | | |\n| - granulocyte | | | |\n| - pancreatic ductal cell | | | |\n| - superficial temporal artery | | | |\n| - gallbladder | | | |\n| Top expressed in | | | |\n| - secondary oocyte | | | |\n| - zygote | | | |\n| - thymus | | | |\n| - primary oocyte | | | |\n| - spleen | | | |\n| - ileum | | | |\n| - zone of skin | | | |\n| - jejunum | | | |\n| - esophagus | | | |\n| - colon | | | |\n| More reference expression data | [https://www.bgee.org/gene/ENSG00000163599](https://www.bgee.org/gene/ENSG00000163599) | | |\n| BioGPS | | | |\n| More reference expression data | [http://biogps.org/gene/1493/](http://biogps.org/gene/1493/) | | |\n\n| Gene ontology | |\n|---------------|-|\n| Molecular function | - [protein binding](http://amigo.geneontology.org/amigo/term/GO:0005515) |\n| Cellular component | - [perinuclear region of cytoplasm](http://amigo.geneontology.org/amigo/term/GO:0048471)\u003cbr\u003e- [integral component of membrane](http://amigo.geneontology.org/amigo/term/GO:0016021)\u003cbr\u003e- [clathrin-coated endocytic vesicle](http://amigo.geneontology.org/amigo/term/GO:0045334)\u003cbr\u003e- [plasma membrane](http://amigo.geneontology.org/amigo/term/GO:0005886)\u003cbr\u003e- [Golgi apparatus](http://amigo.geneontology.org/amigo/term/GO:0005794)\u003cbr\u003e- [membrane](http://amigo.geneontology.org/amigo/term/GO:0016020)\u003cbr\u003e- [external side of plasma membrane](http://amigo.geneontology.org/amigo/term/GO:0009897)\u003cbr\u003e- [protein complex involved in cell adhesion](http://amigo.geneontology.org/amigo/term/GO:0098636)\u003cbr\u003e- [integral component of plasma membrane](http://amigo.geneontology.org/amigo/term/GO:0005887) |\n| Biological process | - [B cell receptor signaling pathway](http://amigo.geneontology.org/amigo/term/GO:0050853)\u003cbr\u003e- [T cell costimulation](http://amigo.geneontology.org/amigo/term/GO:0031295)\u003cbr\u003e- [negative regulation of B cell proliferation](http://amigo.geneontology.org/amigo/term/GO:0030889)\u003cbr\u003e- [adaptive immune response](http://amigo.geneontology.org/amigo/term/GO:0002250)\u003cbr\u003e- [negative regulation of regulatory T cell differentiation](http://amigo.geneontology.org/amigo/term/GO:0045590)\u003cbr\u003e- [immune response](http://amigo.geneontology.org/amigo/term/GO:0006955)\u003cbr\u003e- [cellular response to DNA damage stimulus](http://amigo.geneontology.org/amigo/term/GO:0006974)\u003cbr\u003e- [immune system process](http://amigo.geneontology.org/amigo/term/GO:0002376)\u003cbr\u003e- [positive regulation of apoptotic process](http://amigo.geneontology.org/amigo/term/GO:0043065)\u003cbr\u003e- [negative regulation of immune response](http://amigo.geneontology.org/amigo/term/GO:0050777)\u003cbr\u003e- [negative regulation of T cell proliferation](http://amigo.geneontology.org/amigo/term/GO:0042130)\u003cbr\u003e- [regulation of regulatory T cell differentiation](http://amigo.geneontology.org/amigo/term/GO:0045589)\u003cbr\u003e- [regulation of T cell proliferation](http://amigo.geneontology.org/amigo/term/GO:0042129)\u003cbr\u003e- [T cell receptor signaling pathway](http://amigo.geneontology.org/amigo/term/GO:0050852) |\n| Sources | [Amigo](http://amigo.geneontology.org/) / [QuickGO](https://www.ebi.ac.uk/QuickGO/) |\n\n| Orthologs | | |\n|-----------|-|-|\n| Species | Human | Mouse |\n| Entrez | [1493](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene\u0026cmd=retrieve\u0026dopt=default\u0026list_uids=1493\u0026rn=1) | [12477](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene\u0026cmd=retrieve\u0026dopt=default\u0026list_uids=12477\u0026rn=1) |\n| Ensembl | [ENSG00000163599](http://www.ensembl.org/Homo_sapiens/geneview?gene=ENSG00000163599;db=core) | [ENSMUSG00000026011](http://www.ensembl.org/Mus_musculus/geneview?gene=ENSMUSG00000026011;db=core) |\n| UniProt | [P16410](https://www.uniprot.org/uniprot/P16410) | [P09793](https://www.uniprot.org/uniprot/P09793) |\n| RefSeq (mRNA) | [NM_001037631](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_001037631)\u003cbr\u003e[NM_005214](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_005214) | [NM_001281976](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_001281976)\u003cbr\u003e[NM_009843](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_009843) |\n| RefSeq (protein) | [NP_001032720](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_001032720)\u003cbr\u003e[NP_005205](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_005205) | [NP_001268905](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_001268905)\u003cbr\u003e[NP_033973](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_033973) |\n| Location (UCSC) | [Chr 2: 203.85 – 203.87 Mb](https://genome.ucsc.edu/cgi-bin/hgTracks?org=Human\u0026db=hg38\u0026position=chr2:203853888-203873965) | [Chr 1: 60.93 – 60.95 Mb](https://genome.ucsc.edu/cgi-bin/hgTracks?org=Mouse\u0026db=mm0\u0026position=chr1:60926159-60954991) |\n| PubMed search | [3] | [4] |\n| Wikidata | [View/Edit Human](https://www.wikidata.org/wiki/Q14875744 \"d:Q14875744\") | [View/Edit Mouse](https://www.wikidata.org/wiki/Q14875755 \"d:Q14875755\") |\n\n**Cytotoxic T-lymphocyte associated protein 4** , **(CTLA-4)** also known as **CD152** ([cluster of differentiation](Cluster_of_differentiation \"Cluster of differentiation\") 152), is a [protein receptor](Protein_receptor \"Protein receptor\") that functions as an [immune checkpoint](Immune_checkpoint \"Immune checkpoint\") and downregulates [immune responses](Immune_system \"Immune system\"). CTLA-4 is constitutively expressed in [regulatory T cells](Regulatory_T_cell \"Regulatory T cell\") but only upregulated in conventional [T cells](T_cell \"T cell\") after activation – a phenomenon which is particularly notable in cancers.[5] It acts as an \"off\" switch when bound to [CD80](CD80 \"CD80\") or [CD86](CD86 \"CD86\") on the surface of [antigen-presenting cells](Antigen-presenting_cell \"Antigen-presenting cell\"). It is encoded by the [gene](Gene \"Gene\") _CTLA4_ in humans. \n\nThe CTLA-4 protein is encoded by the _Ctla-4_ gene in mice.[6][7]\n## History\n\nThe CTLA-4 gene was first cloned in 1987 from a cytotoxic T lymphocyte cDNA library, identifying it as a new member of the immunoglobulin superfamily.[6] CTLA-4 was first identified in 1991 as a second receptor for the T cell costimulation ligand B7.[8] In November 1995, the labs of Tak Wah Mak and Arlene Sharpe independently published their findings on the discovery of the function of CTLA-4 as a negative regulator of T-cell activation, by knocking out the gene in mice.[9][10] Previous studies from several labs had used methods which could not definitively define the function of CTLA-4, and were contradictory.[11]\n\nCTLA-4 is a member of the immunoglobulin superfamily that is expressed by activated T cells and transmits an inhibitory signal to T cells. CTLA-4 is homologous to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA-4 binds CD80 and CD86 with greater affinity and avidity than CD28 thus enabling it to outcompete CD28 for its ligands. CTLA-4 transmits an inhibitory signal to T cells,[](https://doi.org/10.1084/jem.182.2.459)[](https://doi.org/10.1084/jem.183.6.2541)[](https://doi.org/10.1016/1074-7613(94)90071-x)[](https://doi.org/10.1126/science.270.5238.985) whereas CD28 transmits a stimulatory signal.[](https://doi.org/10.1038/356607a0)[](https://doi.org/10.1002/(SICI)1521-4141(199911)29:11\u003c3596::AID-IMMU3596\u003e3.0.CO;2-Y) CTLA-4 is also found in regulatory T cells (Tregs) and contributes to their inhibitory function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4. \n\nThe mechanism by which CTLA-4 acts in T cells involves both cell-intrinsic and cell-extrinsic pathways. CTLA-4 recruits phosphatases such as SHP-2 to the T cell receptor (TCR), attenuating the signal by dephosphorylating key molecules like p52 SHC.[](https://doi.org/10.1126/science.282.5397.2263)[](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.608024/full) More recent work has shown that CTLA-4 functions in vivo by capturing and removing CD80 and CD86 from the membranes of antigen-presenting cells via trans-endocytosis, thus making these unavailable for triggering of CD28.[](https://doi.org/10.1126/science.1202947)\n\nIn addition to that, it has been found that dendritic cell (DC) - Treg interaction causes sequestration of Fascin-1, an actin-bundling protein essential for immunological synapse formation and skews Fascin-1–dependent actin polarization in antigen presenting DCs toward the Treg cell adhesion zone. Although it is reversible upon T regulatory cell disengagement, this sequestration of essential cytoskeletal components causes a lethargic state of DCs, leading to reduced T cell priming. This suggests Treg-mediated immune suppression is a multi-step process. In addition to CTLA-4 CD80/CD86 interaction, fascin-dependent polarization of the cytoskeleton towards DC-Treg immune synapse may play a pivotal role.[](https://doi.org/10.1084/jem.20160620)\n\nCTLA-4 may also function via modulation of cell motility and/or signaling through PI3 kinase.[](https://doi.org/10.1371/journal.pone.0031391) Early multiphoton microscopy studies observing T-cell motility in intact lymph nodes appeared to give evidence for the so-called ‘reverse-stop signaling model’.[](https://doi.org/10.1126/science.1131078) In this model CTLA-4 reverses the TCR-induced ‘stop signal’ needed for firm contact between T cells and antigen-presenting cells (APCs).[](https://doi.org/10.1111/j.1600-065X.2009.00770.x) However, those studies compared CTLA-4 positive cells, which are predominantly regulatory cells and are at least partially activated, with CTLA-4 negative naive T cells. The disparity of these cells in multiple regards may explain some of these results. Other groups who have analyzed the effect of antibodies to CTLA-4 in vivo have concluded little or no effect upon motility in the context of anergic T-cells.[](https://doi.org/10.1038/ni.1790) Antibodies to CTLA-4 may exert additional effects when used in vivo, by binding and thereby depleting regulatory T cells.[](https://doi.org/10.1084/jem.20130579)\n## Structure\n\nThe protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. The intracellular domain is similar to that of CD28, in that it has no intrinsic catalytic activity and contains one YVKM motif able to bind PI3K, PP2A and SHP-2 and one proline-rich motif able to bind SH3 containing proteins.\n## Clinical significance\n\nVariants in this gene have been associated with [Type 1 diabetes](Type_1_diabetes \"Type 1 diabetes\"), [Graves' disease](Graves'_disease \"Graves' disease\"), [Hashimoto's thyroiditis](Hashimoto's_thyroiditis \"Hashimoto's thyroiditis\"), [celiac disease](Coeliac_disease \"Coeliac disease\"), [systemic lupus erythematosus](Systemic_lupus_erythematosus \"Systemic lupus erythematosus\"), thyroid-associated orbitopathy, [primary biliary cirrhosis](Primary_biliary_cirrhosis \"Primary biliary cirrhosis\") and other [autoimmune diseases](Autoimmune_disease \"Autoimmune disease\").\n\nPolymorphisms of the CTLA-4 gene are associated with autoimmune diseases such as [rheumatoid arthritis](Rheumatoid_arthritis \"Rheumatoid arthritis\"), [25] autoimmune thyroid disease and multiple sclerosis, though this association is often weak. In systemic lupus erythematosus (SLE), the splice variant sCTLA-4 is found to be aberrantly produced and found in the serum of patients with active SLE.\n\n### Germline haploinsufficiency\n\n[Germline](Germline \"Germline\") [haploinsufficiency](Haploinsufficiency \"Haploinsufficiency\") of CTLA-4 leads to CTLA-4 deficiency or [CHAI disease](CHAI_disease \"CHAI disease\") (CTLA4 haploinsufficiency with [autoimmune](Autoimmune \"Autoimmune\") infiltration), a rare genetic disorder of the immune system. This may cause a dysregulation of the immune system and may result in lymphoproliferation, autoimmunity, [hypogammaglobulinemia](Hypogammaglobulinemia \"Hypogammaglobulinemia\"), recurrent infections, and may slightly increase one’s risk of [lymphoma](Lymphoma \"Lymphoma\"). CTLA-4 mutations have first been described by a collaboration between the groups of Dr. Gulbu Uzel, Dr. Steven Holland, and Dr. Michael Lenardo from the [National Institute of Allergy and Infectious Disease](National_Institute_of_Allergy_and_Infectious_Disease \"National Institute of Allergy and Infectious Disease\"), Dr. Thomas Fleisher from the [NIH Clinical Center](NIH_Clinical_Center \"NIH Clinical Center\") at the [National Institutes of Health](National_Institutes_of_Health \"National Institutes of Health\"), and their collaborators in 2014.[26] In the same year a collaboration between the groups of Dr. Bodo Grimbacher, Dr. Shimon Sakaguchi, Dr. Lucy Walker and Dr. David Sansom and their collaborators described a similar phenotype.[27]\n\nCTLA-4 mutations are inherited in an [autosomal dominant](Autosomal_dominant \"Autosomal dominant\") manner. This means a person only needs one abnormal gene from one parent. The one normal copy is not enough to compensate for the one abnormal copy. Dominant inheritance means most families with CTLA-4 mutations have affected relatives in each [generation](Generation \"Generation\") on the side of the family with the [mutation](Mutation \"Mutation\").\n\n#### Clinical and laboratory manifestations\n\nSymptomatic patients with CTLA-4 mutations are characterized by an immune dysregulation syndrome including extensive [T cell](T_cell \"T cell\") infiltration in a number of organs, including the gut, lungs, bone marrow, central nervous system [28][29] and kidneys. Most patients have diarrhea or [enteropathy](Enteropathy \"Enteropathy\"). [Lymphadenopathy](Lymphadenopathy \"Lymphadenopathy\") and [hepatosplenomegaly](Hepatosplenomegaly \"Hepatosplenomegaly\") are also common, as is autoimmunity. The organs affected by autoimmunity vary but include [thrombocytopenia](Thrombocytopenia \"Thrombocytopenia\"), [hemolytic anemia](Hemolytic_anemia \"Hemolytic anemia\"), [thyroiditis](Thyroiditis \"Thyroiditis\"), type I diabetes, [psoriasis](Psoriasis \"Psoriasis\"), and [arthritis](Arthritis \"Arthritis\"). Respiratory infections are also common. Importantly, the clinical presentations and disease courses are variable with some individuals severely affected, whereas others show little manifestation of disease. This “[variable expressivity](Expressivity_\\(genetics\\) \"Expressivity \\(genetics\\)\"),” even within the same family, can be striking and may be explained by differences in lifestyle, exposure to pathogens, treatment efficacy, or other genetic modifiers.[26][27][30][31] This condition is described to have incomplete penetrance of disease. [Penetrance](Penetrance \"Penetrance\") is said to be incomplete when some individuals fail to express the trait and seem completely asymptomatic, even though they carry the allele. The penetrance is estimated to be about 60%.\n\nThe clinical symptoms are caused by abnormalities of the immune system. Most patients develop reduced levels of at least one [immunoglobulin](Immunoglobulin \"Immunoglobulin\") isotype, and have low CTLA-4 protein expression in T regulatory cells, hyperactivation of effector T cells, low switched [memory B cells](Memory_B_cells \"Memory B cells\"), and progressive loss of circulating B cells.[26][27][31]\n\n#### Treatment\n\nOnce a diagnosis is made, the treatment is based on an individual’s clinical condition and may include standard management for autoimmunity and immunoglobulin deficiencies, such as immunosuppressive therapies and immunoglobulin replacement. Abatacept, a fusion protein of CTLA-4 and an antibody portion of IgG1, has been used for symptomatic control. A 2016 study reported treatment of a Korean CHAI disease patient with abatacept, which controlled immune activity, improved severe anemia and diarrhea (3 L/day), and ended a 3-year hospitalization.[31] For severe cases, hematopoietic stem cell transplantation (HSCT) is a potentially curative option, with a 2024 European study reporting 76.7% 3-year overall survival and remission in most surviving patients. [](https://doi.org/10.1016/j.jaci.2024.08.020) Emerging approaches include autologous gene therapy to restore CTLA-4 expression, which is in early development as of 2024. [](https://sabaiglobal.com/gene-therapy-in-action-ctla4-haploinsufficiency/)\n\n### Agonists to reduce immune activity\n\nThe comparatively higher binding affinity of CTLA-4 than that of CD28 has made CTLA-4 a potential therapy for [autoimmune diseases](Autoimmune_diseases \"Autoimmune diseases\"). Fusion proteins of CTLA-4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.[32] The fusion protein CTLA4-Ig is commercially available as Orencia ([abatacept](Abatacept \"Abatacept\")). A second generation form of CTLA4-Ig known as [belatacept](Belatacept \"Belatacept\") was approved by the FDA in 2011 based on favorable results from the randomized Phase III BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First Line Immunosuppression Trial) study. It was approved for renal transplantation in Epstein-Barr virus (EBV) seropositive patients.\n\n### Antagonists to increase immune activity\n\nConversely, there is increasing interest in the possible therapeutic benefits of blocking CTLA-4 (using antagonistic antibodies against CTLA such as [ipilimumab](Ipilimumab \"Ipilimumab\")—FDA approved for melanoma in 2011—as a means of inhibiting immune system tolerance to tumours and thereby providing a potentially useful immunotherapy strategy for patients with cancer).[5] This therapy was the first approved [immune checkpoint blockade](Immune_checkpoint_blockade \"Immune checkpoint blockade\") therapy.[33] Another is [tremelimumab](Tremelimumab \"Tremelimumab\").[5]\n\nThe 2018 [Nobel Prize in Physiology or Medicine](Nobel_Prize_in_Physiology_or_Medicine \"Nobel Prize in Physiology or Medicine\") was awarded to [James P. Allison](James_P._Allison \"James P. Allison\") and [Tasuku Honjo](Tasuku_Honjo \"Tasuku Honjo\") \"for their discovery of cancer therapy by inhibition of negative immune regulation\".[34]\n## Interactions\n\nCTLA-4 has been shown to interact with: \n\n- AP2M1,[35][36]\n- CD80,[37][38]\n- CD86,[](https://www.uniprot.org/uniprotkb/P16410/entry)\n- PPP2R5A.[39]."])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761886527292,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"_**a**_ _**b**_ _**c**_ [GRCh38: Ensembl release 89: ENSG00000163599](http://May2017.archive.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000163599) – [Ensembl](Ensembl_genome_database_project \\\"Ensembl genome database project\\\"), May 2017\",\"description\":\"1. ^ _**a**_ _**b**_ _**c**_ [GRCh38: Ensembl release 89: ENSG00000163599](http://May2017.archive.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000163599) – [Ensembl](Ensembl_genome_database_project \\\"Ensembl genome database project\\\"), May 2017\",\"url\":\"http://May2017.archive.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000163599\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"_**a**_ _**b**_ _**c**_ [GRCm38: Ensembl release 89: ENSMUSG00000026011](http://May2017.archive.ensembl.org/Mus_musculus/Gene/Summary?db=core;g=ENSMUSG00000026011) – [Ensembl](Ensembl_genome_database_project \\\"Ensembl genome database project\\\"), May 2017\",\"description\":\"2. ^ _**a**_ _**b**_ _**c**_ [GRCm38: Ensembl release 89: ENSMUSG00000026011](http://May2017.archive.ensembl.org/Mus_musculus/Gene/Summary?db=core;g=ENSMUSG00000026011) – [Ensembl](Ensembl_genome_database_project \\\"Ensembl genome database project\\\"), May 2017\",\"url\":\"http://May2017.archive.ensembl.org/Mus_musculus/Gene/Summary?db=core;g=ENSMUSG00000026011\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"** [\\\"Human PubMed Reference:\\\"](https://www.ncbi.nlm.nih.gov/sites/entrez?db=gene\u0026cmd=Link\u0026LinkName=gene_pubmed\u0026from_uid=1493). _National Center for Biotechnology Information, U.S. National Library of Medicine_.\",\"description\":\"3. **^** [\\\"Human PubMed Reference:\\\"](https://www.ncbi.nlm.nih.gov/sites/entrez?db=gene\u0026cmd=Link\u0026LinkName=gene_pubmed\u0026from_uid=1493). _National Center for Biotechnology Information, U.S. National Library of Medicine_.\",\"url\":\"https://www.ncbi.nlm.nih.gov/sites/entrez?db=gene\u0026cmd=Link\u0026LinkName=gene_pubmed\u0026from_uid=1493\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"** [\\\"Mouse PubMed Reference:\\\"](https://www.ncbi.nlm.nih.gov/sites/entrez?db=gene\u0026cmd=Link\u0026LinkName=gene_pubmed\u0026from_uid=12477). _National Center for Biotechnology Information, U.S. National Library of Medicine_.\",\"description\":\"4. **^** [\\\"Mouse PubMed Reference:\\\"](https://www.ncbi.nlm.nih.gov/sites/entrez?db=gene\u0026cmd=Link\u0026LinkName=gene_pubmed\u0026from_uid=12477). _National Center for Biotechnology Information, U.S. National Library of Medicine_.\",\"url\":\"https://www.ncbi.nlm.nih.gov/sites/entrez?db=gene\u0026cmd=Link\u0026LinkName=gene_pubmed\u0026from_uid=12477\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"_**a**_ _**b**_ _**c**_ Syn NL, Teng MW, Mok TS, Soo RA (December 2017). \\\"De-novo and acquired resistance to immune checkpoint targeting\\\". _The Lancet. Oncology_. **18** (12): e731 – e741. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/s1470-2045(17)30607-1](https://doi.org/10.1016%2Fs1470-2045%2817%2930607-1). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29208439](https://pubmed.ncbi.nlm.nih.gov/29208439).\",\"description\":\"5. ^ _**a**_ _**b**_ _**c**_ Syn NL, Teng MW, Mok TS, Soo RA (December 2017). \\\"De-novo and acquired resistance to immune checkpoint targeting\\\". _The Lancet. Oncology_. **18** (12): e731 – e741. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/s1470-2045(17)30607-1](https://doi.org/10.1016%2Fs1470-2045%2817%2930607-1). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29208439](https://pubmed.ncbi.nlm.nih.gov/29208439).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"** Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P (1987). \\\"A new member of the immunoglobulin superfamily--CTLA-4\\\". _Nature_. **328** (6127): 267–70\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1987Natur.328..267B](https://ui.adsabs.harvard.edu/abs/1987Natur.328..267B). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/328267a0](https://doi.org/10.1038%2F328267a0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [3496540](https://pubmed.ncbi.nlm.nih.gov/3496540). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4316396](https://api.semanticscholar.org/CorpusID:4316396).\",\"description\":\"6. **^** Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P (1987). \\\"A new member of the immunoglobulin superfamily--CTLA-4\\\". _Nature_. **328** (6127): 267–70\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1987Natur.328..267B](https://ui.adsabs.harvard.edu/abs/1987Natur.328..267B). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/328267a0](https://doi.org/10.1038%2F328267a0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [3496540](https://pubmed.ncbi.nlm.nih.gov/3496540). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4316396](https://api.semanticscholar.org/CorpusID:4316396).\",\"url\":\"Bibcode_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"** Dariavach P, Mattéi MG, Golstein P, Lefranc MP (December 1988). \\\"Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains\\\". _European Journal of Immunology_. **18** (12): 1901–5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/eji.1830181206](https://doi.org/10.1002%2Feji.1830181206). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [3220103](https://pubmed.ncbi.nlm.nih.gov/3220103). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [34071559](https://api.semanticscholar.org/CorpusID:34071559).\",\"description\":\"7. **^** Dariavach P, Mattéi MG, Golstein P, Lefranc MP (December 1988). \\\"Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains\\\". _European Journal of Immunology_. **18** (12): 1901–5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/eji.1830181206](https://doi.org/10.1002%2Feji.1830181206). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [3220103](https://pubmed.ncbi.nlm.nih.gov/3220103). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [34071559](https://api.semanticscholar.org/CorpusID:34071559).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"** Bashyam, Hema (June 2007). [\\\"CTLA-4: From conflict to clinic\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118622). _J Exp Med_. **204** (6): 1243. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1084/jem.2046fta](https://doi.org/10.1084%2Fjem.2046fta). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2118622](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118622). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17632849](https://pubmed.ncbi.nlm.nih.gov/17632849).\",\"description\":\"8. **^** Bashyam, Hema (June 2007). [\\\"CTLA-4: From conflict to clinic\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118622). _J Exp Med_. **204** (6): 1243. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1084/jem.2046fta](https://doi.org/10.1084%2Fjem.2046fta). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2118622](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118622). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17632849](https://pubmed.ncbi.nlm.nih.gov/17632849).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118622\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"_**a**_ _**b**_ Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. (November 1995). \\\"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4\\\". _Science_. **270** (5238): 985–8\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1995Sci...270..985W](https://ui.adsabs.harvard.edu/abs/1995Sci...270..985W). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.270.5238.985](https://doi.org/10.1126%2Fscience.270.5238.985). [JSTOR](JSTOR_\\\\(identifier\\\\) \\\"JSTOR \\\\(identifier\\\\)\\\") [2888113](https://www.jstor.org/stable/2888113). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7481803](https://pubmed.ncbi.nlm.nih.gov/7481803). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [45993765](https://api.semanticscholar.org/CorpusID:45993765).\",\"description\":\"9. ^ _**a**_ _**b**_ Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. (November 1995). \\\"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4\\\". _Science_. **270** (5238): 985–8\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1995Sci...270..985W](https://ui.adsabs.harvard.edu/abs/1995Sci...270..985W). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.270.5238.985](https://doi.org/10.1126%2Fscience.270.5238.985). [JSTOR](JSTOR_\\\\(identifier\\\\) \\\"JSTOR \\\\(identifier\\\\)\\\") [2888113](https://www.jstor.org/stable/2888113). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7481803](https://pubmed.ncbi.nlm.nih.gov/7481803). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [45993765](https://api.semanticscholar.org/CorpusID:45993765).\",\"url\":\"Bibcode_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"** Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (November 1995). [\\\"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4\\\"](http://www.cell.com/immunity/pdf/1074-7613\\\\(95\\\\)90125-6.pdf) (PDF). _Immunity_. **3** (5): 541–7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/1074-7613(95)90125-6](https://doi.org/10.1016%2F1074-7613%2895%2990125-6). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7584144](https://pubmed.ncbi.nlm.nih.gov/7584144).\",\"description\":\"10. **^** Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (November 1995). [\\\"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4\\\"](http://www.cell.com/immunity/pdf/1074-7613\\\\(95\\\\)90125-6.pdf) (PDF). _Immunity_. **3** (5): 541–7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/1074-7613(95)90125-6](https://doi.org/10.1016%2F1074-7613%2895%2990125-6). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7584144](https://pubmed.ncbi.nlm.nih.gov/7584144).\",\"url\":\"http://www.cell.com/immunity/pdf/1074-7613\\\\(95\\\\\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"** Pardoll DM (December 2012). [\\\"Immunology beats cancer: a blueprint for successful translation\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659410). _Nature Immunology_. **13** (12): 1129–32\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/ni.2392](https://doi.org/10.1038%2Fni.2392). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4659410](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659410). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23160205](https://pubmed.ncbi.nlm.nih.gov/23160205).\",\"description\":\"11. **^** Pardoll DM (December 2012). [\\\"Immunology beats cancer: a blueprint for successful translation\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659410). _Nature Immunology_. **13** (12): 1129–32\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/ni.2392](https://doi.org/10.1038%2Fni.2392). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4659410](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659410). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23160205](https://pubmed.ncbi.nlm.nih.gov/23160205).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659410\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"** Krummel MF, Allison JP (August 1995). [\\\"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192127). _The Journal of Experimental Medicine_. **182** (2): 459–65\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1084/jem.182.2.459](https://doi.org/10.1084%2Fjem.182.2.459). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2192127](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192127). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7543139](https://pubmed.ncbi.nlm.nih.gov/7543139).\",\"description\":\"12. **^** Krummel MF, Allison JP (August 1995). [\\\"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192127). _The Journal of Experimental Medicine_. **182** (2): 459–65\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1084/jem.182.2.459](https://doi.org/10.1084%2Fjem.182.2.459). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2192127](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192127). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7543139](https://pubmed.ncbi.nlm.nih.gov/7543139).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192127\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"** Walunas TL, Bakker CY, Bluestone JA (June 1996). [\\\"CTLA-4 ligation blocks CD28-dependent T cell activation\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192609). _The Journal of Experimental Medicine_. **183** (6): 2541–50\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1084/jem.183.6.2541](https://doi.org/10.1084%2Fjem.183.6.2541). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2192609](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192609). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8676075](https://pubmed.ncbi.nlm.nih.gov/8676075).\",\"description\":\"13. **^** Walunas TL, Bakker CY, Bluestone JA (June 1996). [\\\"CTLA-4 ligation blocks CD28-dependent T cell activation\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192609). _The Journal of Experimental Medicine_. **183** (6): 2541–50\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1084/jem.183.6.2541](https://doi.org/10.1084%2Fjem.183.6.2541). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2192609](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192609). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8676075](https://pubmed.ncbi.nlm.nih.gov/8676075).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192609\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"** Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. (August 1994). \\\"CTLA-4 can function as a negative regulator of T cell activation\\\". _Immunity_. **1** (5): 405–13\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/1074-7613(94)90071-x](https://doi.org/10.1016%2F1074-7613%2894%2990071-x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7882171](https://pubmed.ncbi.nlm.nih.gov/7882171).\",\"description\":\"14. **^** Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. (August 1994). \\\"CTLA-4 can function as a negative regulator of T cell activation\\\". _Immunity_. **1** (5): 405–13\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/1074-7613(94)90071-x](https://doi.org/10.1016%2F1074-7613%2894%2990071-x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7882171](https://pubmed.ncbi.nlm.nih.gov/7882171).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"** Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (April 1992). \\\"CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones\\\". _Nature_. **356** (6370): 607–9\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1992Natur.356..607H](https://ui.adsabs.harvard.edu/abs/1992Natur.356..607H). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/356607a0](https://doi.org/10.1038%2F356607a0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [1313950](https://pubmed.ncbi.nlm.nih.gov/1313950). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4333730](https://api.semanticscholar.org/CorpusID:4333730).\",\"description\":\"15. **^** Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (April 1992). \\\"CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones\\\". _Nature_. **356** (6370): 607–9\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1992Natur.356..607H](https://ui.adsabs.harvard.edu/abs/1992Natur.356..607H). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/356607a0](https://doi.org/10.1038%2F356607a0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [1313950](https://pubmed.ncbi.nlm.nih.gov/1313950). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4333730](https://api.semanticscholar.org/CorpusID:4333730).\",\"url\":\"Bibcode_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"** Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y (November 1999). [\\\"A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells\\\"](https://doi.org/10.1002%2F%28SICI%291521-4141%28199911%2929%3A11%3C3596%3A%3AAID-IMMU3596%3E3.0.CO%3B2-Y). _European Journal of Immunology_. **29** (11): 3596–602\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/(SICI)1521-4141(199911)29:11\u003c3596::AID-IMMU3596\u003e3.0.CO;2-Y](https://doi.org/10.1002%2F%28SICI%291521-4141%28199911%2929%3A11%3C3596%3A%3AAID-IMMU3596%3E3.0.CO%3B2-Y). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [10556814](https://pubmed.ncbi.nlm.nih.gov/10556814).\",\"description\":\"16. **^** Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y (November 1999). [\\\"A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells\\\"](https://doi.org/10.1002%2F%28SICI%291521-4141%28199911%2929%3A11%3C3596%3A%3AAID-IMMU3596%3E3.0.CO%3B2-Y). _European Journal of Immunology_. **29** (11): 3596–602\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/(SICI)1521-4141(199911)29:11\u003c3596::AID-IMMU3596\u003e3.0.CO;2-Y](https://doi.org/10.1002%2F%28SICI%291521-4141%28199911%2929%3A11%3C3596%3A%3AAID-IMMU3596%3E3.0.CO%3B2-Y). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [10556814](https://pubmed.ncbi.nlm.nih.gov/10556814).\",\"url\":\"https://doi.org/10.1002%2F%28SICI%291521-4141%28199911%2929%3A11%3C3596%3A%3AAID-IMMU3596%3E3.0.CO%3B2-Y\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"** Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. (December 1998). [\\\"Molecular basis of T cell inactivation by CTLA-4\\\"](https://doi.org/10.1126%2Fscience.282.5397.2263). _Science_. **282** (5397): 2263–6\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1998Sci...282.2263L](https://ui.adsabs.harvard.edu/abs/1998Sci...282.2263L). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.282.5397.2263](https://doi.org/10.1126%2Fscience.282.5397.2263). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9856951](https://pubmed.ncbi.nlm.nih.gov/9856951).\",\"description\":\"17. **^** Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. (December 1998). [\\\"Molecular basis of T cell inactivation by CTLA-4\\\"](https://doi.org/10.1126%2Fscience.282.5397.2263). _Science_. **282** (5397): 2263–6\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1998Sci...282.2263L](https://ui.adsabs.harvard.edu/abs/1998Sci...282.2263L). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.282.5397.2263](https://doi.org/10.1126%2Fscience.282.5397.2263). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9856951](https://pubmed.ncbi.nlm.nih.gov/9856951).\",\"url\":\"https://doi.org/10.1126%2Fscience.282.5397.2263\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. (April 2011). [\\\"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198051). _Science_. **332** (6029): 600–3\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2011Sci...332..600Q](https://ui.adsabs.harvard.edu/abs/2011Sci...332..600Q). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.1202947](https://doi.org/10.1126%2Fscience.1202947). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3198051](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198051). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21474713](https://pubmed.ncbi.nlm.nih.gov/21474713).\",\"description\":\"18. **^** Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. (April 2011). [\\\"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198051). _Science_. **332** (6029): 600–3\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2011Sci...332..600Q](https://ui.adsabs.harvard.edu/abs/2011Sci...332..600Q). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.1202947](https://doi.org/10.1126%2Fscience.1202947). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3198051](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198051). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21474713](https://pubmed.ncbi.nlm.nih.gov/21474713).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198051\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** Chen J, Ganguly A, Mucsi AD, Meng J, Yan J, Detampel P, et al. (February 2017). [\\\"Strong adhesion by regulatory T cells induces dendritic cell cytoskeletal polarization and contact-dependent lethargy\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294852). _The Journal of Experimental Medicine_. **214** (2): 327–338\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1084/jem.20160620](https://doi.org/10.1084%2Fjem.20160620). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5294852](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294852). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28082358](https://pubmed.ncbi.nlm.nih.gov/28082358).\",\"description\":\"19. **^** Chen J, Ganguly A, Mucsi AD, Meng J, Yan J, Detampel P, et al. (February 2017). [\\\"Strong adhesion by regulatory T cells induces dendritic cell cytoskeletal polarization and contact-dependent lethargy\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294852). _The Journal of Experimental Medicine_. **214** (2): 327–338\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1084/jem.20160620](https://doi.org/10.1084%2Fjem.20160620). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5294852](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294852). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28082358](https://pubmed.ncbi.nlm.nih.gov/28082358).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294852\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"** Knieke K, Lingel H, Chamaon K, Brunner-Weinzierl MC (2012). [\\\"Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295805). _PLOS ONE_. **7** (3): e31391. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2012PLoSO...731391K](https://ui.adsabs.harvard.edu/abs/2012PLoSO...731391K). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1371/journal.pone.0031391](https://doi.org/10.1371%2Fjournal.pone.0031391). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3295805](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295805). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22412835](https://pubmed.ncbi.nlm.nih.gov/22412835).\",\"description\":\"20. **^** Knieke K, Lingel H, Chamaon K, Brunner-Weinzierl MC (2012). [\\\"Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295805). _PLOS ONE_. **7** (3): e31391. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2012PLoSO...731391K](https://ui.adsabs.harvard.edu/abs/2012PLoSO...731391K). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1371/journal.pone.0031391](https://doi.org/10.1371%2Fjournal.pone.0031391). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3295805](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295805). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22412835](https://pubmed.ncbi.nlm.nih.gov/22412835).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295805\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. (September 2006). \\\"Reversal of the TCR stop signal by CTLA-4\\\". _Science_. **313** (5795): 1972–5\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2006Sci...313.1972S](https://ui.adsabs.harvard.edu/abs/2006Sci...313.1972S). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.1131078](https://doi.org/10.1126%2Fscience.1131078). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16931720](https://pubmed.ncbi.nlm.nih.gov/16931720). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [27123046](https://api.semanticscholar.org/CorpusID:27123046).\",\"description\":\"21. **^** Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. (September 2006). \\\"Reversal of the TCR stop signal by CTLA-4\\\". _Science_. **313** (5795): 1972–5\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2006Sci...313.1972S](https://ui.adsabs.harvard.edu/abs/2006Sci...313.1972S). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.1131078](https://doi.org/10.1126%2Fscience.1131078). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16931720](https://pubmed.ncbi.nlm.nih.gov/16931720). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [27123046](https://api.semanticscholar.org/CorpusID:27123046).\",\"url\":\"Bibcode_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"** Rudd CE, Taylor A, Schneider H (May 2009). [\\\"CD28 and CTLA-4 coreceptor expression and signal transduction\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186963). _Immunological Reviews_. **229** (1): 12–26\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1600-065X.2009.00770.x](https://doi.org/10.1111%2Fj.1600-065X.2009.00770.x). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4186963](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186963). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19426212](https://pubmed.ncbi.nlm.nih.gov/19426212).\",\"description\":\"22. **^** Rudd CE, Taylor A, Schneider H (May 2009). [\\\"CD28 and CTLA-4 coreceptor expression and signal transduction\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186963). _Immunological Reviews_. **229** (1): 12–26\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1600-065X.2009.00770.x](https://doi.org/10.1111%2Fj.1600-065X.2009.00770.x). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4186963](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186963). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19426212](https://pubmed.ncbi.nlm.nih.gov/19426212).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186963\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"** Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. (November 2009). [\\\"Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778301). _Nature Immunology_. **10** (11): 1185–92\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/ni.1790](https://doi.org/10.1038%2Fni.1790). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2778301](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778301). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19783989](https://pubmed.ncbi.nlm.nih.gov/19783989).\",\"description\":\"23. **^** Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. (November 2009). [\\\"Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778301). _Nature Immunology_. **10** (11): 1185–92\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/ni.1790](https://doi.org/10.1038%2Fni.1790). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2778301](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778301). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19783989](https://pubmed.ncbi.nlm.nih.gov/19783989).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778301\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"** Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. (August 2013). [\\\"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754863). _The Journal of Experimental Medicine_. **210** (9): 1695–710\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1084/jem.20130579](https://doi.org/10.1084%2Fjem.20130579). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3754863](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754863). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23897981](https://pubmed.ncbi.nlm.nih.gov/23897981).\",\"description\":\"24. **^** Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. (August 2013). [\\\"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754863). _The Journal of Experimental Medicine_. **210** (9): 1695–710\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1084/jem.20130579](https://doi.org/10.1084%2Fjem.20130579). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3754863](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754863). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23897981](https://pubmed.ncbi.nlm.nih.gov/23897981).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754863\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"** Westra HJ, Martínez-Bonet M, Onengut-Gumuscu S, Lee A, Luo Y, Teslovich N, et al. (October 2018). [\\\"Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364548). _Nature Genetics_. **50** (10): 1366–1374\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/s41588-018-0216-7](https://doi.org/10.1038%2Fs41588-018-0216-7). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6364548](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364548). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30224649](https://pubmed.ncbi.nlm.nih.gov/30224649).\",\"description\":\"25. **^** Westra HJ, Martínez-Bonet M, Onengut-Gumuscu S, Lee A, Luo Y, Teslovich N, et al. (October 2018). [\\\"Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364548). _Nature Genetics_. **50** (10): 1366–1374\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/s41588-018-0216-7](https://doi.org/10.1038%2Fs41588-018-0216-7). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6364548](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364548). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30224649](https://pubmed.ncbi.nlm.nih.gov/30224649).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364548\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"_**a**_ _**b**_ _**c**_ Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. (September 2014). [\\\"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371526). _Science_. **345** (6204): 1623–1627\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2014Sci...345.1623K](https://ui.adsabs.harvard.edu/abs/2014Sci...345.1623K). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.1255904](https://doi.org/10.1126%2Fscience.1255904). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4371526](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371526). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25213377](https://pubmed.ncbi.nlm.nih.gov/25213377).\",\"description\":\"26. ^ _**a**_ _**b**_ _**c**_ Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. (September 2014). [\\\"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371526). _Science_. **345** (6204): 1623–1627\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2014Sci...345.1623K](https://ui.adsabs.harvard.edu/abs/2014Sci...345.1623K). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.1255904](https://doi.org/10.1126%2Fscience.1255904). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4371526](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371526). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25213377](https://pubmed.ncbi.nlm.nih.gov/25213377).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371526\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"_**a**_ _**b**_ _**c**_ Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. (December 2014). [\\\"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668597). _Nature Medicine_. **20** (12): 1410–1416\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nm.3746](https://doi.org/10.1038%2Fnm.3746). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4668597](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668597). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25329329](https://pubmed.ncbi.nlm.nih.gov/25329329).\",\"description\":\"27. ^ _**a**_ _**b**_ _**c**_ Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. (December 2014). [\\\"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668597). _Nature Medicine_. **20** (12): 1410–1416\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nm.3746](https://doi.org/10.1038%2Fnm.3746). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4668597](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668597). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25329329](https://pubmed.ncbi.nlm.nih.gov/25329329).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668597\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"** Kaninia S, Grammatikos A, Urankar K, Renowden SA, Patel NK, Gompels MM, Rice CM (August 2021). [\\\"CNS demyelination associated with immune dysregulation and a novel _CTLA-4_ variant\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358566). _Multiple Sclerosis_. **27** (9): 1464–1467\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1177/1352458520963896](https://doi.org/10.1177%2F1352458520963896). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8358566](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358566). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34097529](https://pubmed.ncbi.nlm.nih.gov/34097529).\",\"description\":\"28. **^** Kaninia S, Grammatikos A, Urankar K, Renowden SA, Patel NK, Gompels MM, Rice CM (August 2021). [\\\"CNS demyelination associated with immune dysregulation and a novel _CTLA-4_ variant\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358566). _Multiple Sclerosis_. **27** (9): 1464–1467\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1177/1352458520963896](https://doi.org/10.1177%2F1352458520963896). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8358566](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358566). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34097529](https://pubmed.ncbi.nlm.nih.gov/34097529).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358566\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"** Grammatikos A, Johnston S, Rice CM, Gompels M (August 2021). [\\\"A Family with a Novel CTLA4 Haploinsufficiency Mutation and Neurological Symptoms\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310858). _Journal of Clinical Immunology_. **41** (6): 1411–1416\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s10875-021-01027-1](https://doi.org/10.1007%2Fs10875-021-01027-1). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8310858](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310858). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33956248](https://pubmed.ncbi.nlm.nih.gov/33956248).\",\"description\":\"29. **^** Grammatikos A, Johnston S, Rice CM, Gompels M (August 2021). [\\\"A Family with a Novel CTLA4 Haploinsufficiency Mutation and Neurological Symptoms\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310858). _Journal of Clinical Immunology_. **41** (6): 1411–1416\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s10875-021-01027-1](https://doi.org/10.1007%2Fs10875-021-01027-1). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8310858](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310858). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33956248](https://pubmed.ncbi.nlm.nih.gov/33956248).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310858\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"** Zeissig S, Petersen BS, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, et al. (December 2015). [\\\"Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512923). _Gut_. **64** (12): 1889–97\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1136/gutjnl-2014-308541](https://doi.org/10.1136%2Fgutjnl-2014-308541). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4512923](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512923). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25367873](https://pubmed.ncbi.nlm.nih.gov/25367873).\",\"description\":\"30. **^** Zeissig S, Petersen BS, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, et al. (December 2015). [\\\"Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512923). _Gut_. **64** (12): 1889–97\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1136/gutjnl-2014-308541](https://doi.org/10.1136%2Fgutjnl-2014-308541). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4512923](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512923). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25367873](https://pubmed.ncbi.nlm.nih.gov/25367873).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512923\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"_**a**_ _**b**_ _**c**_ Lee S, Moon JS, Lee CR, Kim HE, Baek SM, Hwang S, et al. (January 2016). [\\\"Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4\\\"](https://doi.org/10.1016%2Fj.jaci.2015.08.036). _The Journal of Allergy and Clinical Immunology_. **137** (1): 327–330\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.jaci.2015.08.036](https://doi.org/10.1016%2Fj.jaci.2015.08.036). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26478010](https://pubmed.ncbi.nlm.nih.gov/26478010).\",\"description\":\"31. ^ _**a**_ _**b**_ _**c**_ Lee S, Moon JS, Lee CR, Kim HE, Baek SM, Hwang S, et al. (January 2016). [\\\"Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4\\\"](https://doi.org/10.1016%2Fj.jaci.2015.08.036). _The Journal of Allergy and Clinical Immunology_. **137** (1): 327–330\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.jaci.2015.08.036](https://doi.org/10.1016%2Fj.jaci.2015.08.036). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26478010](https://pubmed.ncbi.nlm.nih.gov/26478010).\",\"url\":\"https://doi.org/10.1016%2Fj.jaci.2015.08.036\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"** Westhovens R, et al. (2004). [\\\"Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833769). _[Arthritis Research\u0026 Therapy](Arthritis_Research_%26_Therapy \\\"Arthritis Research \u0026 Therapy\\\")_. **6** (Suppl 1): 86. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/ar1128](https://doi.org/10.1186%2Far1128). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2833769](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833769).\",\"description\":\"32. **^** Westhovens R, et al. (2004). [\\\"Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833769). _[Arthritis Research\u0026 Therapy](Arthritis_Research_%26_Therapy \\\"Arthritis Research \u0026 Therapy\\\")_. **6** (Suppl 1): 86. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/ar1128](https://doi.org/10.1186%2Far1128). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2833769](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833769).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833769\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"** Pardoll DM (March 2012). [\\\"The blockade of immune checkpoints in cancer immunotherapy\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023). _Nature Reviews. Cancer_. **12** (4): 252–64\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nrc3239](https://doi.org/10.1038%2Fnrc3239). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4856023](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22437870](https://pubmed.ncbi.nlm.nih.gov/22437870).\",\"description\":\"33. **^** Pardoll DM (March 2012). [\\\"The blockade of immune checkpoints in cancer immunotherapy\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023). _Nature Reviews. Cancer_. **12** (4): 252–64\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nrc3239](https://doi.org/10.1038%2Fnrc3239). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4856023](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22437870](https://pubmed.ncbi.nlm.nih.gov/22437870).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"** [\\\"The Nobel Prize in Physiology or Medicine 2018\\\"](https://www.nobelprize.org/prizes/medicine/2018/summary/). _NobelPrize.org_. Retrieved 3 July 2023.\",\"description\":\"34. **^** [\\\"The Nobel Prize in Physiology or Medicine 2018\\\"](https://www.nobelprize.org/prizes/medicine/2018/summary/). _NobelPrize.org_. Retrieved 3 July 2023.\",\"url\":\"https://www.nobelprize.org/prizes/medicine/2018/summary/\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"** Follows ER, McPheat JC, Minshull C, Moore NC, Pauptit RA, Rowsell S, et al. (October 2001). [\\\"Study of the interaction of the medium chain mu 2 subunit of the clathrin-associated adapter protein complex 2 with cytotoxic T-lymphocyte antigen 4 and CD28\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222163). _The Biochemical Journal_. **359** (Pt 2): 427–34\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1042/0264-6021:3590427](https://doi.org/10.1042%2F0264-6021%3A3590427). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1222163](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222163). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11583591](https://pubmed.ncbi.nlm.nih.gov/11583591).\",\"description\":\"35. **^** Follows ER, McPheat JC, Minshull C, Moore NC, Pauptit RA, Rowsell S, et al. (October 2001). [\\\"Study of the interaction of the medium chain mu 2 subunit of the clathrin-associated adapter protein complex 2 with cytotoxic T-lymphocyte antigen 4 and CD28\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222163). _The Biochemical Journal_. **359** (Pt 2): 427–34\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1042/0264-6021:3590427](https://doi.org/10.1042%2F0264-6021%3A3590427). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1222163](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222163). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11583591](https://pubmed.ncbi.nlm.nih.gov/11583591).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222163\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"** Chuang E, Alegre ML, Duckett CS, Noel PJ, Vander Heiden MG, Thompson CB (July 1997). [\\\"Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression\\\"](https://doi.org/10.4049%2Fjimmunol.159.1.144). _Journal of Immunology_. **159** (1): 144–51\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4049/jimmunol.159.1.144](https://doi.org/10.4049%2Fjimmunol.159.1.144). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9200449](https://pubmed.ncbi.nlm.nih.gov/9200449). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [25449038](https://api.semanticscholar.org/CorpusID:25449038).\",\"description\":\"36. **^** Chuang E, Alegre ML, Duckett CS, Noel PJ, Vander Heiden MG, Thompson CB (July 1997). [\\\"Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression\\\"](https://doi.org/10.4049%2Fjimmunol.159.1.144). _Journal of Immunology_. **159** (1): 144–51\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4049/jimmunol.159.1.144](https://doi.org/10.4049%2Fjimmunol.159.1.144). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9200449](https://pubmed.ncbi.nlm.nih.gov/9200449). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [25449038](https://api.semanticscholar.org/CorpusID:25449038).\",\"url\":\"https://doi.org/10.4049%2Fjimmunol.159.1.144\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"** Peach RJ, Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A, Linsley PS (September 1995). [\\\"Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28\\\"](https://doi.org/10.1074%2Fjbc.270.36.21181). _The Journal of Biological Chemistry_. **270** (36): 21181–7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1074/jbc.270.36.21181](https://doi.org/10.1074%2Fjbc.270.36.21181). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7545666](https://pubmed.ncbi.nlm.nih.gov/7545666).\",\"description\":\"37. **^** Peach RJ, Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A, Linsley PS (September 1995). [\\\"Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28\\\"](https://doi.org/10.1074%2Fjbc.270.36.21181). _The Journal of Biological Chemistry_. **270** (36): 21181–7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1074/jbc.270.36.21181](https://doi.org/10.1074%2Fjbc.270.36.21181). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7545666](https://pubmed.ncbi.nlm.nih.gov/7545666).\",\"url\":\"https://doi.org/10.1074%2Fjbc.270.36.21181\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"** Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, et al. (March 2001). \\\"Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses\\\". _Nature_. **410** (6828): 608–11\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2001Natur.410..608S](https://ui.adsabs.harvard.edu/abs/2001Natur.410..608S). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/35069118](https://doi.org/10.1038%2F35069118). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11279502](https://pubmed.ncbi.nlm.nih.gov/11279502). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4329622](https://api.semanticscholar.org/CorpusID:4329622).\",\"description\":\"38. **^** Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, et al. (March 2001). \\\"Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses\\\". _Nature_. **410** (6828): 608–11\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2001Natur.410..608S](https://ui.adsabs.harvard.edu/abs/2001Natur.410..608S). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/35069118](https://doi.org/10.1038%2F35069118). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11279502](https://pubmed.ncbi.nlm.nih.gov/11279502). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4329622](https://api.semanticscholar.org/CorpusID:4329622).\",\"url\":\"Bibcode_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"** Baroja ML, Vijayakrishnan L, Bettelli E, Darlington PJ, Chau TA, Ling V, et al. (May 2002). [\\\"Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A\\\"](https://doi.org/10.4049%2Fjimmunol.168.10.5070). _Journal of Immunology_. **168** (10): 5070–8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4049/jimmunol.168.10.5070](https://doi.org/10.4049%2Fjimmunol.168.10.5070). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11994459](https://pubmed.ncbi.nlm.nih.gov/11994459).\",\"description\":\"39. **^** Baroja ML, Vijayakrishnan L, Bettelli E, Darlington PJ, Chau TA, Ling V, et al. (May 2002). [\\\"Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A\\\"](https://doi.org/10.4049%2Fjimmunol.168.10.5070). _Journal of Immunology_. **168** (10): 5070–8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4049/jimmunol.168.10.5070](https://doi.org/10.4049%2Fjimmunol.168.10.5070). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11994459](https://pubmed.ncbi.nlm.nih.gov/11994459).\",\"url\":\"https://doi.org/10.4049%2Fjimmunol.168.10.5070\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"This work remains unconfirmed in the literature since its first publication.\",\"explanation\":\"The 1998 study [17] proposed that CTLA-4 recruits a phosphatase (SHP-2) to the TCR to attenuate signaling. However, subsequent research has confirmed this as an accepted cell-intrinsic mechanism of CTLA-4-mediated inhibition, including recruitment of SHP-2 and PP2A to dephosphorylate key signaling molecules. Claiming it remains unconfirmed misrepresents the current consensus in immunology reviews.\",\"fixedText\":\"Revise to state that CTLA-4 recruits phosphatases such as SHP-2 to the TCR, attenuating the signal, as an established mechanism. Retain citation [17] and consider adding a recent review citation.\",\"evidenceSource\":\"Recent review: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.608024/full; https://pmc.ncbi.nlm.nih.gov/articles/PMC10367421/\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The section discusses multiple mechanisms but does not explicitly note that CTLA-4 exerts both cell-intrinsic (direct signaling in T cells) and cell-extrinsic (e.g., trans-endocytosis depleting ligands on APCs) inhibitory effects, which is a key aspect of its function highlighted in recent reviews. This gap leaves the description incomplete for understanding its comprehensive role.\",\"fixedText\":\"Add a sentence clarifying that CTLA-4 inhibition occurs via both cell-intrinsic signaling (e.g., phosphatase recruitment) and cell-extrinsic mechanisms (e.g., ligand removal), citing a recent source.\",\"evidenceSource\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10367421/\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"A second generation form of CTLA4-Ig known as belatacept was recently approved by the FDA\\\"\",\"explanation\":\"The approval occurred in 2011, which is not recent as of 2025. This misrepresents the timeline and could mislead on the maturity of the therapy.\",\"fixedText\":\"Remove \\\"recently\\\" and specify the approval year: \\\"approved by the FDA in 2011\\\"\",\"evidenceSource\":\"[web:11] FDA Approves NULOJIX® (belatacept) - 2011\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"\\\"approved for renal transplantation in patients that are sensitized to Epstein–Barr virus (EBV)\\\"\",\"explanation\":\"The approval is specifically for Epstein-Barr virus (EBV) seropositive patients, not \\\"sensitized\\\" (which typically refers to HLA sensitization in transplants). This imprecise terminology could confuse clinical applicability and risks, as it is contraindicated in EBV seronegative patients due to post-transplant lymphoproliferative disorder risk.\",\"fixedText\":\"Correct to: \\\"approved for renal transplantation in Epstein-Barr virus (EBV) seropositive patients\\\"\",\"evidenceSource\":\"[web:13] NULOJIX FDA label: Contraindicated in EBV seronegative\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\\\"Once a diagnosis is made, the treatment is based on an individual’s clinical condition and may include standard management for autoimmunity and immunoglobulin deficiencies. A study reported in 2016 treated a Korean CHAI disease patient with abatacept... Regular administration of abatacept improved the patient’s severe anemia and diarrhea (3L/day) and brought 3-year-long hospitalization to an end.\\\"\",\"explanation\":\"The section focuses on a single 2016 case of abatacept treatment but omits more established and recent options like hematopoietic stem cell transplantation (HSCT), which has shown effectiveness with 76.7% 3-year overall survival and remission in most patients per a 2024 European study. Emerging gene therapy is also in development as of 2024. This gap leaves incomplete guidance on treatment options for a rare, serious disorder, potentially affecting clinical decision-making.\",\"fixedText\":\"Add information on HSCT as a potentially curative option for severe cases, citing the 2024 study, and mention gene therapy in early development. Retain abatacept info but contextualize as symptomatic management.\",\"evidenceSource\":\"[web:10] Hematopoietic stem cell transplantation for CTLA-4 insufficiency (2024); [web:2] Gene Therapy in Action: CTLA4 Haploinsufficiency (2024)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"* [CD86](CD86 \\\"CD86\\\"),\",\"explanation\":\"The claim of interaction with CD86 lacks a supporting citation, compromising verifiability of a key functional interaction essential to CTLA-4's role as an immune checkpoint.\",\"fixedText\":\"Add a citation to an authoritative source confirming the interaction, such as the UniProt entry or a primary reference like ref 12 which discusses CTLA-4 binding to CD80/CD86.\",\"evidenceSource\":\"UniProt P16410: \\\"Binds to CD80/B7-1 and CD86/B7.2.\\\"\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"* [SHP-2](SHP-2 \\\"SHP-2\\\"), and\",\"explanation\":\"The claim implies a direct protein-protein interaction, but evidence shows no direct binding between CTLA-4 and SHP-2 (PTPN11); any association is indirect, e.g., via PI3K. This misrepresents the signaling mechanism.\",\"fixedText\":\"Remove the SHP-2 interaction claim as it is unsupported and factually inaccurate for direct interaction.\",\"evidenceSource\":\"PubMed 10694513: Phosphorylation fails to allow SHP-2 SH2 domain binding; Trends Immunol (2015) review: \\\"no direct interaction between CTLA-4 and SHP-2\\\".\"}],\"slug\":\"Cytotoxic_T-lymphocyte_associated_protein_4\",\"title\":\"Cytotoxic T-lymphocyte associated protein 4\",\"content\":\"$1f\",\"description\":\"Cytotoxic T-lymphocyte associated protein 4\\n\\n| Available structures | |\\n|----------------------|-|\\n| PDB | Ortholog search: PDBe RCSB |\\n| List of PDB id codes | 3OSK, 1AH1, 1H6E, 1I85, 1I8L, 2X44,...\",\"metadata\":{\"categories\":[\"CTLA-4\",\"CD152\",\"Cytotoxic T-lymphocyte antigen 4\"],\"lastModified\":\"1761553076\",\"contentLength\":\"20742\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"59435\",\"recentViews\":\"59435\",\"dailyAvgViews\":1981.1666259765625,\"qualityScore\":1,\"lastViewed\":\"1761886526\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761886527289,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Cytotoxic_T-lymphocyte_associated_protein_4\"],\"queryHash\":\"[\\\"page\\\",\\\"Cytotoxic_T-lymphocyte_associated_protein_4\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Cytotoxic T-lymphocyte associated protein 4\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Cytotoxic T-lymphocyte associated protein 4 , (CTLA-4) also known as CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA-4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers.[5] It acts as an \\\"off\\\" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. It is encoded by...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"CTLA-4, CD152, Cytotoxic T-lymphocyte antigen 4\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Cytotoxic_T-lymphocyte_associated_protein_4\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Cytotoxic T-lymphocyte associated protein 4\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Cytotoxic T-lymphocyte associated protein 4 , (CTLA-4) also known as CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA-4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers.[5] It acts as an \\\"off\\\" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. It is encoded by...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Cytotoxic_T-lymphocyte_associated_protein_4\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Cytotoxic T-lymphocyte associated protein 4\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:13.076Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Cytotoxic T-lymphocyte associated protein 4\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Cytotoxic T-lymphocyte associated protein 4 , (CTLA-4) also known as CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA-4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers.[5] It acts as an \\\"off\\\" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. It is encoded by...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ODFkMjE0ZTUtYTkyYi00YmZiLWJmNTYtY2EyNzZiOTE4MDMw">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Cytotoxic_T-lymphocyte_associated_protein_4\"}]}]\n"])</script></body></html>